Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 ...

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

Phase 3 trial data showed elegrobart significantly improved proptosis and diplopia in patients with moderate to severe chronic thyroid eye disease.

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.

The Canada Revenue Agency (CRA) probably knows what you did last summer — and last spring, winter and fall. Long before you file your taxes, the agency assembles a substantial profile that can be ...

Earnings call Roche delivered robust Q1 2026 results with group sales up 6% at constant exchange rates (CER), driven by Pharma (+7%) and Diagnostics (+3%, +5% ex-China). Management reaffirmed ...

The note was found after the [child predator] financier was found with a strip of cloth around his neck in July 2019, he ...

Brandi Jones has over two decades of experience as a nurse in an acute care setting. Her clinical background includes pediatrics, medical-surgical, and women's health. She also specializes in ...

Businesses clamoring for tariff refunds can officially start the application process — and about $166 billion is up for grabs. The U.S. government on Monday launched CAPE (Consolidated Administration ...

The Justice Department’s Office of Inspector General says it will audit the department’s compliance with a law mandating the public release of the Epstein files. The audit, initiated by the acting ...

The Government Accountability Office (GAO) will conduct a review of the Department of Justice’s (DOJ) compliance with Congress’s mandate to release the Jeffrey Epstein files, the congressional ...